BackgroundIntrapulmonary pharmacokinetics may better explain response to tuberculosis (TB) treatment than plasma pharmacokinetics. We explored these relationships by modeling bacillary clearance in sputum in adult patients on first-line treatment in Malawi.MethodsBacillary elimination rates (BER) were estimated using linear mixed-effects modelling of serial time-to-positivity in mycobacterial growth indicator tubes for sputum collected during the intensive phase of treatment (weeks 0-8) for microbiologically confirmed TB. Population pharmacokinetic models used plasma and intrapulmonary drug levels at 8 and 16 weeks. Pharmacokinetic-pharmacodynamic relationships were investigated using individual-level measures of drug exposure (area-under-t...
The aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with...
There are contrasting data in the literature about antituberculosis plasma drug concentrations in HI...
Background There is scant evidence to support target drug exposures for optimal tuberculosis outcome...
This work was supported by a Wellcome Trust Clinical PhD Fellowship [grant number 105392/B/14/Z to A...
BACKGROUND: Intrapulmonary pharmacokinetics may better explain response to tuberculosis (TB) treatme...
BACKGROUND: Further work is required to understand the intrapulmonary pharmacokinetics of first-line...
Background: Further work is required to understand the intrapulmonary pharmacokinetics of first-line...
BACKGROUND: This study aims to explore relationships between baseline demographic covariates, plasma...
Background This study aims to explore relationships between baseline demographic covariates, plasma...
Background. Early mortality among hospitalized HIV-associated tuberculosis (TB/HIV) patients is high...
Includes bibliographical references (leaves 190-203).A prospectlve pharmacokinetic study was conduct...
This pharmacokinetic sub-study was nested within the phase-III OFLOTUB study investigating the short...
This work was supported by the European and Developing Countries Clinical Trials partnership (grants...
Background: Shorter, more efficacious, treatments for pulmonary tuberculosis (TB) are required. Know...
Exposure to lower-than-therapeutic levels of anti-tuberculosis drugs is likely to cause selection of...
The aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with...
There are contrasting data in the literature about antituberculosis plasma drug concentrations in HI...
Background There is scant evidence to support target drug exposures for optimal tuberculosis outcome...
This work was supported by a Wellcome Trust Clinical PhD Fellowship [grant number 105392/B/14/Z to A...
BACKGROUND: Intrapulmonary pharmacokinetics may better explain response to tuberculosis (TB) treatme...
BACKGROUND: Further work is required to understand the intrapulmonary pharmacokinetics of first-line...
Background: Further work is required to understand the intrapulmonary pharmacokinetics of first-line...
BACKGROUND: This study aims to explore relationships between baseline demographic covariates, plasma...
Background This study aims to explore relationships between baseline demographic covariates, plasma...
Background. Early mortality among hospitalized HIV-associated tuberculosis (TB/HIV) patients is high...
Includes bibliographical references (leaves 190-203).A prospectlve pharmacokinetic study was conduct...
This pharmacokinetic sub-study was nested within the phase-III OFLOTUB study investigating the short...
This work was supported by the European and Developing Countries Clinical Trials partnership (grants...
Background: Shorter, more efficacious, treatments for pulmonary tuberculosis (TB) are required. Know...
Exposure to lower-than-therapeutic levels of anti-tuberculosis drugs is likely to cause selection of...
The aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with...
There are contrasting data in the literature about antituberculosis plasma drug concentrations in HI...
Background There is scant evidence to support target drug exposures for optimal tuberculosis outcome...